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Central nervous system control of energy balance affects susceptibility to obesity and diabetes, but how fatty 
acids, malonyl-CoA, and other metabolites act at this site to alter metabolism is poorly understood. Phar-
macological inhibition of fatty acid synthase (FAS), rate limiting for de novo lipogenesis, decreases appetite 
independently of leptin but also promotes weight loss through activities unrelated to FAS inhibition. Here we 
report that the conditional genetic inactivation of FAS in pancreatic β cells and hypothalamus produced lean, 
hypophagic mice with increased physical activity and impaired hypothalamic PPARα signaling. Administra-
tion of a PPARα agonist into the hypothalamus increased PPARα target genes and normalized food intake. 
Inactivation of β cell FAS enzyme activity had no effect on islet function in culture or in vivo. These results 
suggest a critical role for brain FAS in the regulation of not only feeding, but also physical activity, effects that 
appear to be mediated through the provision of ligands generated by FAS to PPARα. Thus, 2 diametrically 
opposed proteins, FAS (induced by feeding) and PPARα (induced by starvation), unexpectedly form an inte-
grative sensory module in the central nervous system to orchestrate energy balance.
*OUSPEVDUJPO
Higher organisms adapt to changes in energy needs by assimilating 
peripheral hormonal and nutritional cues and integrating them in 
the central nervous system (1, 2). Even subtle defects in this sys-
tem have deleterious consequences since modest excess weight in 
humans is associated with increased mortality (3, 4). The most 
thermodynamically efficient strategy for weight loss is appetite 
suppression, a difficult goal given the diversity of factors regulat-
ing food intake, ranging from amines and peptides to metabolites 
and fatty acids (reviewed in ref. 5).
Fatty acid metabolism affects feeding behavior. Malonyl-CoA, 
an intermediary substrate controlling fatty acid flux, and carnitine 
palmitoyltransferase-1 (CPT-1), which allows fatty acids access to 
mitochondria for β-oxidation, have been independently implicat-
ed in regulating appetite (6, 7). Pharmacological inhibition of fatty 
acid synthase (FAS), the multifunctional enzyme that utilizes mal-
onyl-CoA for the first committed step in fatty acid biosynthesis 
(8), with the compound C75 produces anorexia and weight loss in 
mice in the setting of increased malonyl-CoA (9). However, recent 
studies indicate that these effects on malonyl-CoA alone may not 
be sufficient to induce anorexia, as C75 also has an impact on the 
sympathetic nervous system and metabolic mediators, including 
PPARα and PPARγ coactivator-1 α (PGC1α) (10, 11). In addition, 
CNS glucose metabolism is required for the anorexic actions 
of C75 (12). How multiple disparate events related to fatty acid 
metabolism in the CNS coordinate energy balance is uncertain.
Previous studies have linked appetite and pancreatic β cell func-
tion. Chronic i.c.v. insulin infusion reduces food intake and body 
weight (13). Genetic disruption of insulin receptor substrate 2 in 
β cells and the hypothalamus using rat insulin 2 promoter Cre 
(RIPCre) transgenic mice mated with floxed insulin receptor sub-
strate 2 mice increases appetite as well as body weight and causes 
diabetes (14, 15). Constitutive activation of CPT-1 in pancreatic 
islets suppresses glucose-stimulated insulin secretion (16) whereas 
inhibition of CPT-1 in the hypothalamus (which increases long-
chain fatty acyl-CoAs) decreases hepatic gluconeogenesis and food 
intake (17). Since many of the same factors appear to regulate food 
intake and β cell function, a common mechanism could integrate 
glucose metabolism and feeding behavior.
FAS is one such potential integrative mediator. It is regulated 
by glucose, insulin, amino acids, fatty acids, leptin, and other 
metabolites directly involved in energy balance (18–20). FAS 
is increased in animal models of obesity and insulin-resistant 
diabetes (21), and a sequence variant in FAS is associated with 
altered adiposity in humans (22). FAS expression is ubiquitous 
and essential for life since global inactivation of the FAS gene 
in mice is embryonic lethal at the preimplantation stage (23). 
Recent studies using liver-specific FAS knockout mice suggest 
that products of the FAS reaction (as yet unidentified) regulate 
hepatic glucose and lipid metabolism by serving as endogenous 
activators of the nuclear receptor PPARα (24). These findings 
and others (23, 25) suggest that de novo lipogenesis produces a 
distinct regulatory pool of fatty acids.
To determine whether FAS in pancreatic β cells and the CNS 
affects glucose metabolism and feeding, we mated floxed FAS mice 
(24) with RIPCre mice (26). We found that FAS is not important 
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protein; CART, cocaine-amphetamine–related transcript; CPT-1, carnitine palmitoyl-
transferase-1; FAS, fatty acid synthase; FASKO mice, mice lacking FAS in pancreatic 
β cells and a diffuse neuronal population within the hypothalamus; Glut2, glucose 
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for pancreatic β cell function but is crucial for coordinating feed-
ing behavior by activating PPARα in the brain.
3FTVMUT
Generation of pancreatic β cell and hypothalamic FAS knockout mice. By 
crossing mice homozygous for the FAS loxP allele (24) with RIP-
Cre mice, we generated FASKO (FAS knockout) mice (Figure 1), 
which were born at the expected frequency. There was no effect of 
genotype on either litter size or birth weights. FAS gene rearrange-
ment was confirmed by PCR using primers (24) that yield a 317-bp 
product when exons 4–8 of the gene are deleted (Figure 1A) and 
was restricted to islets (Figure 1B) and hypothalamus (Figure 1C). 
FAS was not rearranged in other peripheral tissues (Figure 1B), the 
cerebral cortex (Figure 1C), or the cerebellum (Figure 1C) in WT 
or FASKO animals.
We confirmed previous reports (14, 15, 27) of both pancreatic 
β cell and hypothalamic Cre expression with this RIPCre model 
in 2 ways. First, Cre mRNA was detected by quantitative RT-PCR 
only in the hypothalamus and islets of RIPCre and FASKO mice 
(Figure 1D). Second, we crossed the FASKO mice with ROSA26 
animals, a model that allows expression of β-galactosidase in the 
presence of Cre recombinase (28). Expression of β-galactosidase 
was present, as expected, in pancreatic β cells (not shown). Strong 
expression of β-galactosidase was also present in a diffuse popu-
lation of hypothalamic neurons and weakly within the striatum 
(caudate putamen) in FASKO brains (Figure 1E), a pattern that 
is consistent with previous reports (14, 15, 27, 29). However, in 
situ hybridization for FAS message showed that its expression was 
unaffected by genotype in the striatum, substantia nigra, or other 
brain regions analyzed, except within the hypothalamus of FASKO 
mice around the arcuate nucleus and the ventral medial hypothal-
amus (Figure 1, F and G). The decrease in FAS expression in the 
hypothalamus was further quantified and confirmed by quantita-
tive RT-PCR (Figure 1H). The actual degree of neuronal FAS sup-
pression was probably greater than shown in Figure 1H since these 
measurements include glial cells, which would not be expected to 
show gene rearrangement and decreased expression. Brain weight 
(0.43 ± 0.02 g WT versus 0.41 ± 0.02 g FASKO; P = NS, n = 5) and 
overall brain morphology were also similar between genotypes.
Two other lines of evidence indicated that FAS was disrupted in 
pancreatic β cells and hypothalamus. First, FAS enzyme activity 
was decreased and malonyl-CoA levels were increased in isolated 
FASKO islets (Figure 1, I and J). Malonyl-CoA, a FAS substrate, 
would be expected to rise with FAS disruption. FAS enzyme activity 
was unaffected in FASKO epididymal fat and liver (Figure 1I, right 
panel). Second, hypothalamic malonyl-CoA content in the FASKO 
mice was significantly elevated even in the fasted state; levels under 
these conditions should be low, as seen in fasted WT littermates 
(Figure 1K). Collectively, these results are consistent with selective 
inactivation of FAS in pancreatic β cells and the hypothalamus.
Pancreatic β cell function in FASKO mice. Although recent data sug-
gest that Cre expression alone may have nonspecific effects on 
β cell function (30), we found no β cell phenotype in FASKO mice. 
Loss of FAS enzyme activity in FASKO islets (Figure 1I) had no 
effect on glucose and insulin levels during glucose tolerance test-
ing (Figure 2, A–C). When islets were isolated from these mice 
and stimulated with glucose in culture, there was no difference in 
insulin secretion (Figure 2D). Insulin content of whole pancreas as 
well as isolated islets was unaffected by the deletion of β cell FAS 
(Figure 2, E and F). Islets from FASKO mice exhibited normal dis-
tribution of non-β cells at the periphery and insulin-positive cells 
in the core (Figure 2G). Morphometry showed similar β cell mass 
(Figure 2H) and islet size distribution (not shown) in FASKO and 
WT mice. Expression of genes involved in glucose sensing and islet 
function, such as glucokinase (Gck), glucose transporter 2 (Glut2), 
and pancreatic duodenal homeobox-1 (Pdx-1), was unaltered by 
islet FAS inactivation (Figure 2I). Together, these results show that 
FAS is not required for β cell function in adult mice.
Feeding behavior and energy balance in FASKO mice. FASKO mice 
weighed less, but were not runted, compared with their WT lit-
termates (Figure 3, A and B). Their decreased body weight was 
due to decreased adiposity without a genotype effect on percent-
age of lean body mass (Figure 3C). Adiposity is determined by 
the balance between caloric intake and expenditure. Both were 
affected in FASKO mice. Freely feeding FASKO mice ate 17% less 
than control (WT and RIPCre) animals (Figure 4A). To determine 
whether this hypophagia was dependent on feeding state, we 
studied the response of FASKO mice to 24 hours of food depriva-
tion. Compared with ad libitum baseline levels, food intake was 
significantly attenuated at 4 hours and 24 hours after refeeding 
(Figure 4B) in FASKO mice, confirming the hypophagic effect 
of CNS FAS disruption. This genetic alteration did not produce 
visceral illness or aversive behavior, as FASKO mice had nor-
mal water intake (2.03 ± 0.94 versus 1.98 ± 1.05 ml/24 h in WT; 
P = NS, n = 20), body temperature, stool mass and consistency, 
pain threshold (assessed using the hot plate test at 55°C, not 
shown), and corticosterone concentration (Table 1). Serum glu-
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under ad libitum chow-fed and 24-hour–fasted conditions were 
also similar between genotypes (Table 1).
FASKO animals exhibited increased oxygen consumption under 
both fed (Figure 4C) and fasted conditions (Figure 4D). When ani-
mals were tested over a 1-hour period using a computerized pho-
tobeam system, FASKO mice showed significantly increased loco-
motor activity in terms of both total beam breaks (Figure 4E) and 
ambulations (whole-body movements) (Figure 4F). They also had 
increased ambulation over a 24-hour period (Figure 4G), with the 
greatest differences being manifested during the dark phase, the 
same time period during which maximal differences in oxygen con-
sumption were seen (Figure 4C). Increased oxygen consumption in 
FASKO animals was mainly due to increased physical activity rather 
than intrinsically elevated metabolism in peripheral tissues, since 
substrate oxidation rate, substrate preference (respiratory exchange 
ratio), heat generation, and cold-induced thermogenesis were all 
unaffected by genotype (Table 2). We sought further confirmation 
of increased physical activity by using an infrared sensing tech-
nique to measure home-cage activity over 3 days (Figure 4H). This 
increase in activity was seen only in the FASKO mice and not in the 
control (WT and RIPCre) animals (Figure 4H). Together with hypo-
phagia (Figure 4A), these data suggest that the observed phenotype 
is due to FAS inactivation and not a nonspecific effect of Cre.
FASKO animals also made more entries (Figure 4I), spent more 
time (Figure 4J), and traveled a greater distance (Figure 4K) in the 
center of the open field as compared with WT controls. These 
differences might reflect altered emotionality and not merely a 
generalized hyperactive state because the distance traveled in the 
periphery of the same open-field arena was similar between geno-
types (Figure 4L).
To determine whether hypophagia, increased physical activity, 
or both were responsible for lower body weight in FASKO animals, 
we performed pair-feeding experiments. When WT mice were food 
restricted by pair-feeding to FASKO animals for 7 days, the change 
in their body weight and percentage of fat mass was nearly identi-
cal to that of freely fed FASKO mice (Figure 5, A and B). Percent-
age of lean mass remained unaffected by genotype or pair feeding 
(Figure 5C). Physical activity in the WT pair-fed mice remained the 
same as in ad libitum–fed control mice (WT-Ctrl) and was lower 
than that of FASKO animals (Figure 5D). These results suggest 
that decreased food intake is largely responsible for decreased adi-
posity in FASKO mice. However, they do not eliminate the possi-
bility that, over the long term, increased physical activity of these 
mice also contributes to their decreased adiposity.
Pair feeding WT mice with FASKO animals further decreased 
hypothalamic malonyl-CoA content relative to that of freely fed 
control animals, an appropriate physiologic response to fasting 
(Figure 5E). Serum metabolites and hormones in the WT pair-fed 
mice confirmed the relative fasted state (Table 1). Since, by design, 
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hypothalamic malonyl-CoA content in the FASKO animals (Figure 
5E) suggests that hypophagia in these animals was a consequence 
of hypothalamic FAS inactivation.
Feeding behavior is controlled in part by orexigenic and anorexi-
genic neuropeptides within the arcuate nucleus of the hypothala-
mus, where signals such as insulin and leptin are integrated (1, 
2). In situ hybridization revealed suppression of mRNAs for the 
orexigenic neuropeptides agouti-related protein (AgRP) and neu-
ropeptide Y (NPY) and induction of mRNAs for the anorexigenic 
neuropeptides cocaine-amphetamine–related transcript (CART) 
and proopiomelanocortin (POMC) in FASKO as compared with 
WT arcuate nucleus (Figure 6, A and B). Many hypothalamic 
areas, including the paraventricular nucleus and the lateral hypo-
thalamus, are supplied by axons from the NPY/AgRP neurons in 
'JHVSF
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the arcuate nucleus (31). Therefore, we also assessed melanin-con-
centrating hormone (MCH) and orexin (OX) mRNAs in the lateral 
hypothalamus and CART mRNA in the paraventricular nucleus. In 
contrast to changes in neuropeptide expression seen in the arcu-
ate nucleus, MCH and OX mRNA levels in the lateral hypothalamus 
(Figure 6, A and B) and CART expression in the paraventricular 
nucleus (not shown) were similar between FASKO and control 
animals. Our previous studies (32) showed that pair feeding nor-
mally increases NPY and decreases CART and POMC expression, a 
normal physiological response to fasting (33). In contrast, despite 
their hypophagia, FASKO mice have a hypothalamic neuropeptide 
expression profile (at least in the arcuate nucleus) characteristic of 
the fed state.
FAS activation of brain PPARα coordinates feeding behavior. While 
hypophagic FASKO mice resemble C75-treated WT mice (9, 31), 
C75 also affects the sympathetic nervous system and mediators 
such as PPARα (10, 11). Since hepatic FAS is required for PPARα 
activation (24), we hypothesized that FAS regulates feeding 
through PPARα. We first studied the effects of hypothalamic FAS 
disruption on PPARα expression and its target genes. In contrast 
to limited data regarding the presence of PPARα in the hypothala-
mus (34), we consistently detected PPARα message by quantita-
tive RT-PCR and found no genotype effect (Figure 7A). However, 
message levels of 3 genes known to be induced by PPARα (35, 36), 
acyl-CoA oxidase (ACO), CPT-1, and malonyl-CoA decarboxyl-
ase (MCD, which lowers malonyl-CoA levels), were decreased 
by approximately 50% in FASKO compared with WT hypo-
thalamus (Figure 7A). All of these genes were appropriately 
induced in WT mice pair fed with FASKO animals, reflect-
ing the normal physiologic response to fasting (Figure 7A). 
These data show impaired hypothalamic PPARα activation 
in hypophagic FASKO animals.
If decreased hypothalamic PPARα signaling caused by FAS 
inactivation suppresses food intake (Figure 4B), then admin-
istration of Wy14,643 (a potent PPARα agonist) near the 
hypothalamus should prevent hypophagia. Since there were 
no previous reports of i.c.v. treatment with Wy14,643, we per-
formed dose-response studies to minimize the likelihood of 
nonspecific effects or visceral illness caused by the drug. The 
lowest effective i.c.v. dose that did not adversely affect food/
water intake and body weight in WT animals was 15 μg (Fig-
ure 7, B–D). Administration of this dose i.c.v. to 23.5-hour 
fasted FASKO mice 30 minutes before the onset of the dark 
cycle caused an increase in 
food intake comparable to 
WT levels over the 24-hour 
refeeding period (Figure 
8, A and B). Differences in 
body weight change between 
FASKO and WT mice were 
also abolished by 4 hours 
(Figure 8, A and B), reflect-
ing increased food intake 
in the FASKO animals with 
i.c.v. PPARα agonist treat-
ment. As compared with 
hypophagic vehicle-treated 
FASKO mice, Wy14,643-
treated FASKO animals had 
higher serum glucose and 
insulin concentrations and lower free fatty acid levels (Table 3), 
consistent with their increased food intake after the 23.5-hour fast 
(Figure 8B). Water intake was not affected by either vehicle or drug 
treatment (not shown).
If FAS affects feeding through PPARα, CNS administration of 
Wy14,643 should restore not only food intake but also expression 
of PPARα target genes. PPARα, ACO, CPT-1, and MCD mRNAs in 
the hypothalamus were induced in FASKO mice at the end of the 
refeeding period (Figure 8C). Wy14,643 given i.c.v. also lowered 
hypothalamic malonyl-CoA (Figure 8D), suggesting that hypo-
thalamic PPARα signaling regulates malonyl-CoA, presumably 
through the induction of MCD (36). To confirm that Wy14,643 
treatment increased food intake in FASKO mice, we subjected 
mice to a crossover protocol in which animals previously treated 
with the drug were given vehicle after a 1-week washout period. 
Withdrawal of PPARα activation in FASKO mice returned feeding 
and body weight to baseline levels (Figure 8, E and F).
To further confirm that PPARα agonist treatment rescues hypo-
phagia in FASKO mice, we injected Wy14,643 into the ventral 
hypothalamus by bilateral stereotaxic injection. To verify appro-
priate delivery to the targeted area, Evans blue, an inert dye, was 
coinjected with the drug, and brain sections were examined for 
the presence of the dye. As illustrated in Figure 9A, 24 hours after 
bilateral stereotaxic injection, dye was detected in the ventral hypo-
5BCMF
Serum chemistries and hormones in free-feeding, pair-fed (PF), and 24-hour fasted WT and FASKO mice
 Free feeding Fast (24 hour)
Parameters WT (n = 8) FASKO (n = 8) WT-PF (n = 8) WT (n = 8) FASKO (n = 8)
Glucose (mg/dl) 156.5 ± 4.1 144.6 ± 7.2 119.1 ± 7.8A 107.1 ± 6.1 97.5 ± 10.6
Free fatty acids (mEq/l) 0.77 ± 0.05 0.74 ± 0.07 1.27 ± 0.07A 2.29 ± 0.12 1.99 ± 0.24
Triglycerides (mg/dl) 95.6 ± 14.1 104.2 ± 15.9 67.4 ± 5.1A 37.4 ± 5.1 58.2 ± 11.1
Cholesterol (mg/dl) 105.2 ± 4.4 88.6 ± 6.1 89.0 ± 5.2 79.0 ± 5.2 68.5 ± 4.9
Insulin (ng/ml) 1.13 ± 0.25 1.04 ± 0.21 0.65 ± 0.06A 0.51 ± 0.10 0.40 ± 0.12
Leptin (ng/ml) 1.37 ± 0.24 1.69 ± 0.33 ND 0.53 ± 0.14 0.77 ± 0.13




Metabolic parameters in WT and FASKO mice
Parameters WT FASKO
SOR (pmol 14C-palmitate oxidized/mg/h) 0.89 ± 0.15 1.01 ± 0.18
Respiratory exchange ratio-fed state 0.83 ± 0.09 0.81 ± 0.07
Respiratory exchange ratio-fasted state 0.71 ± 0.05 0.71 ± 0.06
Heat-fed state (kcal/h) 0.61 ± 0.04 0.56 ± 0.07
Heat-fasted state (kcal/h) 0.49 ± 0.05 0.47 ± 0.04
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thalamus adjacent to and below the third ventricle, a typical pat-
tern for bilateral stereotaxic injections at this site.
As FASKO mice were hypophagic under ad libitum–fed con-
ditions (Figure 4A), we hypothesized that restoration of PPARα 
signaling in freely fed animals would also prevent the hypopha-
gia. Thirty minutes before the onset of the dark cycle, 10 μg of 
Wy14,643 was delivered directly into the ventral hypothalamus 
by bilateral stereotaxic injection, which resulted in increased 
food intake in FASKO mice by 12 hours that was significant-
ly more than in WT at 24 hours (Figure 9, B and C). The body 
weight change was higher in FASKO mice after intrahypothalamic 
Wy14,643 injection as compared to vehicle-treated animals at the 
12-hour and 24-hour time points (Figure 9, B and C), reflecting 
increased food intake and reversal of the baseline hypophagia. As 
with i.c.v. experiments, PPARα and its target genes ACO, CPT-1, 
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tion of Wy14,643 (Figure 9D). However, intrahypothalamic treat-
ment resulted in higher expression of CPT-1 and MCD mRNA lev-
els in FASKO as compared with WT mice (Figure 9D) at the end of 
the 24-hour feeding period, coincident with their increased food 
intake (Figure 9C).
Peripheral administration of Wy14,643 at much higher doses 
is reported to induce anorexia in mice (37). Although effective at 
reversing hypophagia with CNS administration, the same dose of 
Wy14,643 given i.p. did not affect food intake or body weight in 
FASKO mice (Figure 10, A and B). Control mice also maintained 
their baseline food intake and body weight. As expected, i.p. injec-
tion of the PPARα agonist induced PPARα and its target genes in 
the liver (Figure 10C) and jejunum (not shown) but had no effect 
on the same genes in the hypothalamus (Figure 10D), confirming 
that CNS activation of PPARα is required to increase food intake 
in FASKO animals.
Long-chain fatty acids may serve as ligands for PPARα and are 
derived from dietary fat or generated de novo by the FAS reaction. 
To determine whether supplying high levels of fatty acids in the diet 
could activate PPARα and reverse hypophagia in FASKO mice, we fed 
these animals a high-fat diet (42%) for 2 weeks (Figure 11). Though 
food intake in both genotypes was decreased compared with their 
respective baseline levels during this relatively short high-fat feed-
ing period (Figure 11B), hypophagia in FASKO animals persisted 
whether expressed as absolute intake per day (Figure 11A) or as per-
centage change from chow baseline (Figure 11B). This intervention 
also failed to restore the impaired hypothalamic PPARα signaling 
(Figure 11C). FASKO mice remained hypophagic even after 10 weeks 
of high-fat feeding (not shown). Together, these results suggest that 
fatty acids synthesized by FAS but not those provided by dietary fat 
activate PPARα in the brain to affect feeding behavior.
%JTDVTTJPO
FAS is an attractive potential target for obesity therapies because 
it is regulated by major mediators of energy balance and controls 
steady-state levels of substrates affecting food intake. However, 
direct evidence implicating FAS in feeding behavior is lacking 
since pharmacological inhibitors of FAS such as C75 have complex 
effects that include activation of the sympathetic nervous system. 
Our generation of mice with genetic inactivation of FAS in the 
hypothalamus and β cell serendipitously resulted in animals with 
hypophagia and altered behavior with no apparent β cell pheno-
type, allowing us to implicate brain FAS in energy homeostasis 
through its activation of the nuclear receptor PPARα.
The absence of a β cell phenotype in these mice was unexpected. 
De novo lipogenesis through malonyl-CoA is important for insulin 
secretion in HIT cells, a β cell line (38). The malonyl-CoA/CPT-1 
interaction contributes to a metabolic signaling network control-
ling insulin secretion in INS(832/13) cells (16). In contrast with 
these studies in cell lines, our in vivo results using islets with the 
loss of FAS enzyme activity (Figure 1I) and increased malonyl-CoA 
content (Figure 1J) indicate that FAS is not required for β cell func-
tion (Figure 2).
FASKO mice had less adiposity, decreased food intake, and 
increased activity (Figures 3 and 4), prompting the evaluation 
of non-β cell tissues affecting energy homeostasis. We detected 
extraislet Cre expression within the hypothalamus and caudate 
putamen (striatum) (Figure 1E), consistent with results of oth-
ers using the rat insulin 2 promoter to drive Cre (14, 15, 27, 29). 
However, analysis of various brain regions for FAS gene rearrange-
ment and mRNA expression showed that FAS inactivation was 
'JHVSF




























Downloaded on August 12, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/31183
SFTFBSDIBSUJDMF
 The Journal of Clinical Investigation   http://www.jci.org   Volume 117   Number 9   September 2007 
largely restricted to the hypothalamus (Figure 1, B–H). Given the 
absence of an effect on β cell function in FASKO mice, it is likely 
that FAS deletion in the hypothalamus is responsible for the lean 
phenotype. Pair-feeding experiments (Figure 5) indicated that the 
decreased adiposity in FASKO mice was mostly due to their rela-
tive hypophagia rather than increased physical activity. However, 
a minor contribution of physical activity to the lean phenotype 
is plausible given that, despite the relative food restriction of WT 
mice, a nonsignificant trend toward increased adiposity persisted 
(Figure 5B). There is precedence for a link between hypothalamic 
FAS and increased food intake. Pharmacologic activation of the 
cannabinoid receptor 1 promotes feeding in 
association with induction of hypothalamic 
FAS gene expression (39).
Direct evidence for hypothalamic FAS 
mediation of food intake helps unify previous 
observations regarding the role of fatty acid 
metabolism in CNS control of bioenergetics. 
Increased neuronal malonyl-CoA content, inhi-
bition of CPT-1 activity, and the accumulation 
of long-chain fatty acids and their esters have 
been independently reported to suppress appe-
tite (6, 7, 17, 40). These biologic variables are 
interrelated in complex ways. High malonyl-
CoA levels inhibit CPT-1 activity. Decreased 
CPT-1 activity impairs fatty acid metabolism, 
causing the accumulation of long-chain fatty 
acyl-CoAs (7) that inhibit acetyl-CoA carboxyl-
ase (41) and decrease malonyl-CoA levels, since malonyl-CoA is the 
product of the acetyl-CoA carboxylase reaction.
In the current work, we establish a basis for the coordinate regu-
lation of these interrelated mediators. FASKO mice lack normal 
hypothalamic PPARα signaling (Figure 7A), resulting in hypopha-
gia with increased malonyl-CoA content (Figure 1K and Figure 5E) 
and decreased expression of CPT-1 (Figure 7A and Figure 8C) in the 
hypothalamus. Intrahypothalamic and i.c.v. (but not i.p.) admin-
istration of Wy14,643 restored hypothalamic PPARα signaling by 
inducing CPT-1 and MCD (Figure 8C and Figure 9D) and decreas-























Effect of i.c.v. administration of Wy14,643 on serum chemistries and hormones
 Vehicle Wy14,643
Parameters WT (n = 7) FASKO (n = 7) WT (n = 10) FASKO (n = 10)
Glucose (mg/dl) 165.8 ± 5.8 128.6 ± 2.3A 171.2 ± 9.2 168.9 ± 10.5B
Free fatty acids (mEq/l) 0.38 ± 0.04 0.72 ± 0.04A 0.31 ± 0.05 0.40 ± 0.01B
Triglycerides (mg/dl) 96.6 ± 17.2 99.2 ± 14.0 88.7 ± 8.9 92.5 ± 16.1
Cholesterol (mg/dl) 92.5 ± 11.3 93.1 ± 7.0 86.4 ± 6.7 86.0 ± 4.5
Insulin (ng/ml) 4.01 ± 1.4 1.34 ± 0.57A 3.28 ± 1.6 3.01 ± 1.5B
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(Figure 8B and Figure 9C). Fatty acids provided in a high-fat diet 
failed to correct impaired hypothalamic PPARα signaling (Fig-
ure 11C) or reverse hypophagia in FASKO animals (Figure 11A). 
Therefore, fatty acids synthesized by FAS appear to activate PPARα 
in the CNS to coordinate feeding behavior. These results are con-
sistent with the model shown in Figure 12. FAS, known to be 
regulated by several metabolites (glucose, amino acids, fatty acids, 
insulin, and leptin) involved in energy balance (8, 18–20), senses 
nutritional status in the CNS and orchestrates fatty acid metabo-
lism to affect feeding behavior through the nutritionally regulated 
nuclear receptor PPARα.
Why the administration of the PPARα agonist to WT animals does 
not further increase food intake is unclear. Activating PPARα in an 
animal with normal PPARα signaling (as opposed to FASKO ani-
mals with impaired PPARα activation) may prompt compensatory 
changes in the expression of regulatory factors in an attempt to con-
trol food intake. In support of this notion, NPY and AgRP knockout 
mice do not exhibit expected decreases in food intake (42). There is 
no effect on food intake in whole-body PPARα null mice (43).
In addition to their hypophagia, FASKO mice had increased 
oxygen consumption due to enhanced physical activity rather 
than elevation of intrinsic metabolism in peripheral tissues (Fig-
ure 4 and Table 2). These phenotypes are strikingly similar to 
those of MCH and MCH receptor knockout mice, which are also 
hypophagic, lean, and hyperactive (44, 45). In our model, MCH 
mRNA levels in the lateral hypothalamus were unaffected by gen-
otype (Figure 6), but we cannot rule out effects on MCH protein 
levels or MCH receptor signals contributing to the hyperactive 
phenotype of FASKO mice.
FASKO animals also appeared to manifest decreased anxiety-like 
behavior, as demonstrated by their increased number of entries, 
time spent, and distance traveled in the center of an open-field 
arena (Figure 4, I–K). This behavioral change was unexpected, 
since anorexia is commonly associated with increased anxiety-like 
emotionality, as occurs with central infusion of corticotrophin-
releasing factor (46) or glucagon-like peptide 1 (47). Rimonabant, 
a cannabinoid receptor 1 receptor antagonist, causes weight loss 
in humans, complicated by anxiety and depression (48). Unlike 
these interventions, interrupting the hypothalamic FAS-PPARα 
axis suppresses appetite and increases physical activity without 
producing concomitant increases in anxiety-like behaviors, ideal 
side effects for treating human obesity.
In summary, FAS is not required for pancreatic β cell function 
but is critical for the regulation of feeding behavior through the 
activation of PPARα, likely in the hypothalamus. It might seem par-
adoxical that PPARα, a transcription factor that evolved to respond 
to starvation, is regulated by FAS, an enzyme activated by feeding. 
We speculate that it is precisely because of their opposite roles that 
these factors coordinate feeding behavior by forming a negative 
feedback loop between availability of nutrients and their metabo-
lism. The FAS-PPARα axis (Figure 12) may thus represent an evolu-
tionary adaptation to maintain energy homeostasis in response to 
2 of the most primordial stimuli, feeding and starvation.
.FUIPET
Animals. FAS-floxed mice have been described (24). RIPCre mice were 
obtained from The Jackson Laboratory. We used 4- to 5-month-old male 
and female littermate FASKO (Cre positive with the floxed allele) and WT 
(Cre negative with the floxed allele) mice in a mixed (BL/6 and 129) back-
ground for experiments. FAS gene rearrangement was confirmed using 
both PCR and Southern blotting, and mice were genotyped using FAS- and 
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trolled rooms with a 12-hour light/dark cycle with free access to standard 
mouse chow (Purina 5053) and water, unless otherwise specified. Protocols 
followed NIH guidelines and were approved by the Washington University 
Animal Studies Committee.
Locomotor activity and open-field behavior experiments. To determine nor-
mal cage activity in WT and FASKO mice, we used infrared sensors to 
detect body-heat image and its spatial displacement over time (InfraMot; 
TSE Systems). Sensors were mounted on standard mouse cage covers and 
the data analyzed using the InfraMot software (version 1.3) to obtain 
duration and intensity of activity over several days. To evaluate locomo-
tor activity and possible alterations in emotionality, mice were studied 
over a 1-hour period while ambulations were measured over 24 hours in 
transparent (47.6 × 25.4 × 20.6 cm) polystyrene enclosures as described 
(49). Each chamber was surrounded by a frame containing a 4 × 8 matrix 
of photocell pairs, the output of which was analyzed by MotorMonitor 
software (Hamilton-Kinder). The software was used to define a 33 × 11 
cm central zone and a peripheral or surrounding zone that was 5.5 cm 
wide with the sides of the enclosure being the outermost boundary. This 
peripheral area extended along the entire perimeter of the chamber. Vari-
ables that were analyzed included the total number of beam breaks, ambu-
lations (whole-body movements), rearings, entries made, time spent, and 
the distance traveled in the center arena as well as the distance traveled 
in the periphery surrounding the center. All behavioral experiments were 
performed between 8:00 am and noon by 
an observer blinded to genotype.
Feeding studies. For acute experiments, 
we measured food intake and body weight 
over a 24-hour period in mice deprived of 
food for 24 hours that were habituated 
to the experimental setting (individually 
housed mice in metabolic chambers) for at 
least 7 days. Freely fed experimental mice 
were also studied in these metabolic cham-
bers to quantify food and water intake 
and body weight after the acclimatization 
period. Another set of WT mice received an 
amount of food identical to that consumed 
by the FASKO mice (pair fed) for a period 
of 7 days. At the end of each experiment, 
animals were sacrificed, blood collected, 
and brains removed and processed. Ad libitum–feeding studies were also 
performed using a high-fat Western diet (fat content of 42%, TD88137; 
Harlan Teklad) (50). Food-intake data are expressed as a function of lean 
body mass (g0.75).
Analytical and biochemical analyses. Measurements of serum glucose, free 
fatty acids, triglycerides, cholesterol, insulin, and leptin concentrations, 
body composition, and indirect calorimetry as well as glucose and insulin 
tolerance tests were performed as described (24, 50). FAS enzyme activity 
from freshly harvested tissues and malonyl-CoA content from rapidly har-
vested, flash-frozen hypothalamus were assayed as described (24, 33).
Quantitative RT-PCR–based gene expression. RNA isolation, cDNA prepa-
ration, and real-time quantitative PCR were performed as described 
(24). Previously published oligonucleotide primer and TaqMan (Applied 
Biosystems) probe sequences for ribosomal protein L32, glucokinase, 
Glut2, PPARα, ACO, and CPT-1a were used (24). The following primer-
probe sets were used: Cre (forward: TGTTGCCGCGCCATCTG; reverse: 
TTGCTTCAAAAATCCCTTCCA; probe: CACCAGCCAGCTATCAACTC-
GCG), FAS (forward: TCCTGGAACGAGAACACGATCT; reverse: GAGA-
CGTGTCACTCCTGGACTTG; probe: CTCACGCTGCGGAAACTTCAG-
GA-AATG), MCD (forward: AACATCCAGGGCATTGTGAAG; reverse: 
GCGGCGATCCTGTTCCT; probe: AGTGCCCTCCGACTGAAACC-






































Downloaded on August 12, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/31183
SFTFBSDIBSUJDMF
 The Journal of Clinical Investigation   http://www.jci.org   Volume 117   Number 9   September 2007
GCTGTT-GGAGG). Coamplification of the mRNA for the mouse ribo-
somal protein L32, an invariant internal control, was performed in all 
samples. Assays were performed in triplicate, and results normalized to 
L32 mRNA levels.
In situ hybridization. Coronal hypothalamic sections (16 μm) were cut on a 
cryostat and immediately stored at –80°C until hybridization. Oligos specif-
ic for FAS (5ʹ-GGGTCCATTGTGTGTGCCTGCTTGGGGTG-3ʹ), AgRP (5ʹ-
CGACGCGGAGAACGAGACTCGCGGTTCTGTGGATCTAGCACCTC -
3ʹ), NPY (5ʹ-GGGCGTTTTCTGTGCTTTCCTTCATTAAGAGGTCTG-3ʹ), 
CART (5ʹ-ACAGTCACACAGCTTCCCGATCCTGGCCCCTTTC-3ʹ), POMC 
(5ʹ-CTTGATGATGGCGTTCTTGAAGAGCGTCACCAGGGGCGTCTG-
GCTCTT-3ʹ), MCH (5ʹ-CCAACAGGGTCGGTAGACTCGTCCCAGCAT-
3ʹ), and orexin (5ʹ-TTCGTAGAGACGGCAGGAACACGTCTTCTGGCGA-
CA-3ʹ) detection were used. These probes were 3ʹ end labeled with [α-35S] 
2ʹ-deoxyadenosine-5ʹ-0-(1-thiotriphosphate) using terminal deoxynucleo-
tidyl transferase (Amersham Biosciences). In situ hybridization was per-
formed as described (32), using 8 animals per experimental group from 2 
independent experiments.
Stereotaxic surgery and microinjection. Cannulae were implanted i.c.v. under 
ketamine-xylazine anesthesia in WT and FASKO mice in the lateral ven-
tricle (32). In other experiments, we implanted cannulae that were targeted 
bilaterally to the ventral hypothalamus directed to stereotaxic coordinates 
1.6 mm posterior to the bregma, ± 0.4 mm lateral to the midline, and 5.8 
mm below the surface of the skull as previously described (6). After surgery, 
animals were caged individually and allowed to recover for at least a week 
prior to any experiments to ensure their body weight and food intake had 
returned to baseline. Before Wy14,643 (Biomol) administration, 1 set of 
animals was fasted for 23.5 hours (6:00 pm to 5:30 pm) and another main-
tained under ad libitum feeding conditions.
Previously 23.5-hour–fasted WT and FASKO mice received a single i.c.v. 
injection of either Wy14,643 (15 μg dissolved in 2 μl of 20% dimethyl sulf-
oxide in artificial cerebrospinal fluid) or vehicle alone using a Hamilton 
syringe. Thirty minutes after injection, at the start of the dark cycle, chow 
was returned to the cages and food intake measured at 1, 2, 4, 12, and 24 
hours. Body weight was measured immediately before the injection and at 
each of the above time points. At the end of the 24-hour refeeding period, 
each animal received an i.c.v. injection of 1 μl Evans blue dye (0.05% in arti-
ficial CSF) just before sacrifice. Only animals in which the dye was visual-
ized within the third ventricle were included. We performed the study twice 
with a crossover design in which animals that received the drug initially 
also received a vehicle injection a week later.
Freely fed WT and FASKO mice received a single injection through 
bilaterally implanted cannulae of either Wy14,643 (10 μg dissolved in 
a total volume of 2 μl, i.e., 1 μl per side, of 20% dimethyl sulfoxide and 
0.05% Evans blue dye in artificial CSF) or vehicle alone using a Hamil-
ton syringe. Thirty minutes after injection, at the onset of the dark cycle, 
chow was returned to the cages and food intake measured at 4, 12, and 
24 hours. Body weight was measured immediately before the injection 
and at each of the above time points. At the end of the 24-hour feeding 
period, animals were sacrificed, and the location of the cannulae was veri-
fied by noting the presence of Evans blue dye in the ventral hypothalamus. 
Only animals in which the dye was visualized in the hypothalamus were 
included in subsequent analyses.
β-galactosidase staining. FAS-floxed mice with and without Cre were 
crossed with ROSA26 animals (The Jackson Laboratory) to assess the 
distribution of Cre recombinase. Animals were deeply anesthetized with 
i.p. injection of xylazine/ketamine cocktail and perfused with cold PBS, 
followed by cold 0.1 M PBS containing 4% paraformaldehyde. Brain and 
pancreas were dissected and fixed in 4% paraformaldehyde for 2 hours, 
then washed in PBS. Pancreata were frozen in Tissue-Tex OCT (Triangle 
Biomedical Sciences Inc.) compound. Brains were placed in 30% sucrose 
overnight, then frozen in OCT. Coronal cryostat sections (10 μm) were 
thaw mounted on slides, washed for 2 minutes in cold PBS, then placed 
in detergent buffer (2 mM MgCl2, 0.01% sodium deoxycholate, 0.02% IGE-
PAL [Calbiochem] in PBS, pH 7.4) for 15 minutes at room temperature, 
followed by staining solution (2 mM MgCl2, 0.01% sodium deoxycholate, 
0.02% IGEPAL, 5 mM potassium ferricyanide, 5 mM potassium ferrocya-
nide in PBS, pH 7.4, containing 1 mg/ml of galactopyranoside dissolved in 
dimethyl formamide) overnight at 37°C. Cells positive for β-galactosidase 
indicated the presence of Cre.
Pancreas histomorphometry. From euthanized FASKO and WT animals, the 
pancreas was dissected, fixed overnight in Bouin solution, embedded in 
paraffin, and sectioned, and 5-μm sections were mounted on slides. Dual 
immunofluorescence staining with anti-insulin (1:500; Sigma-Aldrich) 
and a mixture of anti-glucagon (1:800; Chemicon International), anti-
pancreatic polypeptide (1:40; Chemicon International), and anti-soma-
tostatin (1:200; Dako) antibodies was performed and visualized using 
the appropriate FITC and Texas red secondary antibodies (51). The β cell 
mass was calculated by point-counting morphometry from a minimum of 
6 insulin-stained sections (5 μm) separated by 200 μm from 3–4 animals 
per genotype using the BIOQUANT Classic98 software package (version 
3.50.6; BIOQUANT Image Analysis Corp.) as described (51).
Islet isolation and insulin secretion. Pancreatic islets from WT and FASKO 
mice were isolated by collagenase digestion (52) and hand picked under a 
microscope. Ten islets per condition were cultured with 3 mM or 20 mM 
glucose, and insulin secreted in the medium was determined (52). Mea-
surement of islet and whole pancreas insulin content was performed by 
acid-ethanol extraction (51, 52).
Fatty acid oxidation. Finely minced (∼0.5 mm thick) liver slices (150 mg) 
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glass vials fitted with center wells containing 2 N NaOH and circular fil-
ter paper (1822-024; Whatman). Tissues were placed at the bottom of the 
vials in 2 ml of Krebs-Ringer buffer (pH 7.4) with 0.4% BSA and 1 μCi (57 
mCi/mmol) of 14C-palmitate (CFA-23; Amersham Biosciences). Vials were 
capped with a rubber septum, and contents of the vial were gassed with 
100% O2 for 10 minutes and incubated at 37°C for 2 hours on a rotatory 
shaker (100 strokes/min). Then, 2 ml of 6 N HCl was injected to release 
14CO2. To ensure adequate transfer of 14CO2 to the NaOH-soaked filter 
paper in the center well, vials were left undisturbed overnight at room 
temperature. The filter paper was then transferred to scintillation fluid 
and counted. The rates of fatty acid oxidation were calculated as pmoles of 
14C-palmitate oxidized per hour per mg of tissue.
Statistics. Values are expressed as mean ± SEM. Statistical comparisons 
were performed using an unpaired, 2-tailed Student’s t test (when 2 
groups were analyzed) or ANOVA. If the overall F value was found to be 
significant for the latter, comparisons between means were made using 
appropriate post-hoc tests.
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